We use cookies to improve your experience. See our Privacy Policy.
Replimune Group, Inc. is a biological products, (no diagnostic substances) company incorporated in DE, trading on the Nasdaq.
Brefyr has analyzed 1 SEC filing for REPL, with the most recent being a 10-Q filed on November 6, 2026. Each filing is scored for significance on a 1-10 scale to help investors quickly identify the most important disclosures.
Exchange
Nasdaq
Sector
Healthcare
Filer Category
Non-accelerated filer<br>Smaller reporting company
Fiscal Year End
March
| Date | Type | Significance | Details |
|---|---|---|---|
| Nov 6, 26 | 10-Q | Routine (0/10) | View |
Replimune Group, Inc. is a biological products, (no diagnostic substances) company incorporated in DE, trading on the Nasdaq.
Brefyr has analyzed 1 SEC filing for REPL, including 10-Q. The most recent filing was a 10-Q filed on November 6, 2026.
No recent insider transactions have been detected in REPL SEC filings.
Replimune Group, Inc. is incorporated in DE and is classified as a Non-accelerated filer<br>Smaller reporting company filer with the SEC.
Replimune Group, Inc.'s fiscal year ends in March. Annual 10-K reports are typically filed within 60-90 days after the fiscal year end.
Last updated: November 6, 2026
Data sourced from SEC EDGAR public filings. For informational purposes only — not investment advice. AI-generated summaries may contain errors. See our full disclaimer.